It has been reported in preclinical models of melanoma that blockade of the VEGF/VEGFR2 pathway increased the anti-tumor activity of adoptively transferred T-cells (Shrimali et al., 2010) and the combination of blocking VEGFR2 by the specific monoclonal antibody DC101 with a cancer vaccination showed a great anti-tumor effect by favoring CD8+ T cell recruitment and reducing the number of regulatory T cells, which have tumor immune-suppressive function (Huang et al., 2012). Here, VEGFA is linked to cancer.